Morphogen-IX Scientific Advisory Board
Martin Wilkins is Professor of Clinical Pharmacology at Imperial College London. He is Vice Dean (Research) for the Faculty of Medicine, a role he combines with Head of the Department of Medicine and Director of the National Institute of Health Research / Wellcome Trust Imperial Clinical Research Facility, which is based at Hammersmith Hospital. His BHF-funded Travelling Fellowship to St Louis USA in 1987 provided the platform for his subsequent career in cardiovascular research. For the past 25 years he has led a bench-to-bedside programme investigating the molecular basis of pulmonary hypertension and evaluating new treatments. His work, supported throughout by the British Heart Foundation, contributed to the development of two new classes of drug for pulmonary hypertension, namely phosphodiesterase inhibitors and soluble guanylate cyclase stimulators, and more recently provided insights into the roles of iron and zinc in pulmonary vascular homeostasis. He was elected to the UK Academy of Medical Sciences in 2015. He holds a Liebig Professorship at the Justus Liebig University of Giessen (since 2014). He was awarded honorary membership of the Kyrgyz National Academy of Sciences (2013). He is a co-founder and Past-President of the Pulmonary Vascular Research Institute, a global network of experts in the field (http://www.pvrinstitute.org).